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Pancreatic cancer is one of the most lethal cancers and
has a global survival rate of less than 5% at 5 years. Surgical
resection remains the only curative measure but provides a
median survival of only 12-15 months, due to the very high
rates of both local recurrence and distant metastases1-3.
On the basis of this natural history, multiple adjuvant and
more recently neoadjuvant therapies have been investigated
in order to improve survival. This review is a critical assess-
ment of the results and limitations of such trials and the aut-
hors discuss a rationale for the introduction of new develop-
ments in the (neo)adjuvant setting of pancreatic cancer. 
Postoperative adjuvant therapy 
The number of large randomised trials remains relatively li-
mited The trials respectively conducted by the Gastrointestinal
Tract cancer Study Group (GITSG) and the EORTC (40891)
evaluated the addition of external-beam radiation therapy
(EBRT) and concomitant 5FU as radiosensitizer after surgical
resection (Table I)4, 5. In both trials, radiation consisted of 40
Gy given as a split course and 5FU given during weeks 1 and
5 The GITSG trial demonstrated a survival advantage for this
multimodal therapy compared to resection alone (20 vs 11
months) but only included 43 patients4. Ever since, adjuvant
chemoradiation with 5FU as radiosensitizer has been consi-
dered in the US as standard of care after curative surgery.
Other US data derived from non-randomized studies also
suggest that adjuvant chemoradiation may prolong median
survival (19.5 vs 13.5 months for historic surgical controls)
and this treatment has been identified as a favourable prog-
nostic factor3, 6, 7. Moreover it has been suggested that conti-
nuous infusionnal 5FU should be preferably used in this set-
ting as there was no significant toxicity observed7.
Between 1987 and 1995, 218 patients were randomized
in the EORTC trial to receive either surgery followed by che-
moradiation (40 Gy in a split course + a 5FU infusion during
2x5 days) or no further treatment after surgery5. Of these,
114 patients had pancreatic head cancer and the rest have
periampullary tumors. The subgroup of pancreatic cancer
patients who had multimodal treatment displayed a trend to-
wards longer median survival than those who had surgery
alone (17 vs 12.6 months) but the study was not sufficiently
powered to demonstrate a statistically significant benefit Con-
sequently, this adjuvant regimen was not considered as a
standard treatment and, in Europe, surgery alone remains
the standard care5.
In a Norwegian study, the role of AMF (Adriamycin, Mi-
tomycin and 5FU) chemotherapy was investigated in the ad-
juvant setting; this study enrolled 61 patients and showed a
significant prolongation of median survival but no difference
at 5 years8.
All these trials raised challenging questions regarding eit-
her the methodology or the treatment regimen used: a) 20 to
24% of the assessable patients did not receive the intended
treatment because of patient refusal, prolonged recovery af-
ter Whipple’s resection or rapid tumour progression, thus in-
troducing a bias into the results; b) no stratification was ma-
de between pancreatic and periampullary tumors which were
mixed up at enrolment; c) the retroperitoneal margins were
not accurately determined; d) compared to continuous radia-
tion and 5FU administration, the treatment regimens, compri-
sing split course radiation and 5 FU bolus, cannot be consi-
dered optimal; e) there was no quality control/standardiza-
tion of surgery and radiotherapy.
Details were recently published of the ESPAC-1 trial, the
largest trial so far conducted in the setting of adjuvant the-
rapy for pancreatic cancer9; this trial assessed the relative ro-
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le of chemotherapy (bolus 5FU + folinic acid, 5 days
monthly), chemoradiation (2x20 Gy over 2 weeks with bolus
5FU) or chemoradiation followed by chemotherapy versus
surgery alone in 541 patients9 (Table I). This trial, however,
was submitted to multiple criticisms for its study design, inter-
pretation of data and control of the quality of the ressources
used; thus, the 541 eligible patients from 51 different centers
were randomized in different ways, in order to increase the
accrual in a pragmatic fashion : 285 were included in a two-
by-two factorial design (70 for chemoradiation, 74 for che-
motherapy, 72 for both,and 69 for observation only); anot-
her 68 patients were randomly assigned to chemoradiation
or non chemoradiation and 188 to chemotherapy or no che-
motherapy.
Results emerging from the two-by-two factorial analysis (n
= 285) did not show longer survival for patients treated with
chemotherapy or chemoradiation compared to observation.
By contrast, when pooling the results for all the patients inclu-
ded in the different randomization options in a somewhat pe-
culiar way, the authors showed evidence of a survival benefit
after adjuvant chemotherapy (median survival :19.5 months
for the 238 patients with chemotherapy vs 14.0 months for
the 235 patients without, p < 0.0005) On the other hand,
there was no difference between the median survival of the
175 patients receiving chemoradiation vs the 178 patients
without chemoradiation (15.5 vs 16.1 months, p=0.024) (Ta-
ble I). Major prognostic factors were involvement of the re-
section margin, tumour grade, tumour size, nodal involve-
ment and administration of chemotherapy.
Should these conclusions affect our view of the role of che-
moradiation after surgery for pancreatic cancer ? As raised
by the accompanying editorial10, this study triggered a great
deal of criticisms and is subject to all the methodological pit-
falls outlined above.
Moreover, because of serious concerns that enough pa-
tients might not be available for the 2x2 randomization in
this trial, the investigators pragmatically added two additio-
nal ways of randomization : chemotherapy vs no chemothe-
rapy and chemoradiation vs no chemoradiation; they also
allowed patients to receive, according to their own or their
physician’s preference additional “background” chemothe-
rapy or chemoradiation that were not part of the study regi-
mens. Subsequently, the results emerged in three parallel
trials in which a high proportion of patients (about 40%) re-
ceived therapies that were not defined when the study star-
ted. All these modifications undoubtedly led to odd classifica-
tions in which “no chemotherapy” patients who had received
chemoradiation were compared to “chemotherapy” patients
who also had received chemoradiation. The same criticism
held true for the “chemoradiation” and “no chemoradiation”
groups. In addition, the inclusion criteria were inconclusive
for the different groups mentioned Therefore it might be con-
ceivable that, due to the interactions of the different thera-
pies, the study is underpowered and does not allow a proper
comparison of the relative regimens.
Consequently, it seems not possible to draw any definite
conclusion from the results of the ESPAC-1 trial as regards
the efficacy of chemoradiation, which was used in a subopti-
mal regimen, in the adjuvant setting of pancreatic cancer In
addition, recommendation of 5FU/folinic acid regimens,
which has displayed extremely low activity in metastatic pan-
creatic cancer, is also not justified after curative resection as
it is unlikely that a treatment that has virtually no activity in
advanced disease is active in the adjuvant setting 11, 12. 
Neoadjuvant therapy
The risk of delaying or not receiving postoperative adju-
vant treatment prompted many investigators to initiate studies
in which chemoradiation using 5FU as a radiosensitizer was
given before surgery (Table II). There might be theoretically
TABLE I
Adjuvant chemoradiation studies in patients with resectable pancreatic cancer
Author (year) (reference) No of patients Randomization Treatment Median survival (months)
GITSG (1985) 21 Yes S + 40 Gy split + 5FU b 20*
(4) 22 S 11
EORTC (1999) 60 Yes S + 40 Gy split + 5FU 2x5 17.1
(5) 54 days 12.6
ESPAC-1 (2001) 69 S
17.8(9) 74 2x2 S + 5FU/FA
70 factorial S + 40 Gy split + 5FU b
15.872 S + both
175 pooled chemoradiotherapy 15.5
178 randomization no chemoradiatherapy 16.1
238 pooled chemotherapy 19.7*
235 randomization no chemotherapy 14
Yeo (1997) 120 no S + 40-55 Gy + 5FU 19.5*
(3) 53 S 13.5
Mehta (2001) 52 no S + 45 Gy + 5FU c 32
(7)
*p significant; S: surgery; 5FU b: bolus 500 mg, 5FU c: continuous infusion 200-250 mg/m2/day (d)
}
}
some tumor-biological advantages of preoperative chemora-
diation especially based on short and intensive course of ra-
diotherapy, but so far, the only reports regarding the accep-
tability and feasability of such therapy concern small non-
randomized series Therefore, most surgeons remain reluctant
into using this approach and prefer the post-operative treat-
ment. The potential advantages of preoperative chemoradia-
tion are:
– 1 increased cell sensitivity to radiation before surgery
due to better oxygenation of the tumor cells 
– 2 no delay of postoperative recovery and postponement
of the planned treatment 
– 3 lower incidence of postoperative anastomotic leaks
– 4 lower rate of positive margin resection (retroperitone-
al) due to downstaging
– 5 avoidance of surgery in patients with evidence of ra-
pidly disseminating disease on restaging after chemo-
radiation (25%) and thus better selection of patients
who will benefit from pancreatic resection.
Several phase II studies have been published They have
shown the feasibility of combining preoperatively radiation
(30 to 50 Gy) and continuous 5FU infusion (300
mg/m2/day)13-15. In one study, toxicity was reduced when
chemoradiation was delivered over 2 weeks up to a total do-
se of 30 Gy (3 Gy/fraction); 20/35 patients underwent suc-
cessful pancreaticoduodenectomy. Local tumour control and
patient survival were equal to the results provided by stan-
dard fractionated chemoradiation (50.4 Gy in 5.5 weeks,
1.8 Gy/fraction); only 10% of the 20 patients resected had a
loco-regional relapse and the median survival for all 20 was
25 months15 (Table II). Another non-randomised study repor-
ted on the survival advantage of preoperative chemoradia-
tion in patients with regional pancreatic cancer; a first group
of 68 patients with proven unresectable pancreatic cancer
was given radiation (40 Gy in split course) combined with
5FU, platinum and streptozocin and 20 of them were then
curatively resected; another group of 91 patients with resec-
table pancreatic cancer underwent surgery first followed by
chemotherapy ± radiation in 63 of them. Median survival
was 23.6 months in the neoadjuvant group compared to 14
for the patients with initial resectable disease (p=0.006) whi-
le the postoperative mortality rates were similar (0 and 5%,
respectively)16. Although these data were based on a histori-
cal control group, they suggest that control of the disease can
be improved by downsizing the tumour through neoadjuvant
therapy. On the other hand, it should be taken into account
that the survival gain emerging from these neoadjuvant stu-
dies may simply result from better selection of patients :
firstly, preoperatively, by accurate staging and secondly, pe-
roperatively when only the good responders benefited from
curative resection.
As toxicity emerging from this approach is moreover not
negligeable, it certainly needs further refinement and more
data on feasibility before embarking into large randomized
trials. Also, the elaboration of neoadjuvant strategies for
combined modality treatments calls for the following require-
ments:
• a proper definition of inclusion criteria
• a proven pancreatic adenocarcinoma (by histology or
cytology)
• an accurate definition of resectability of the tumor by a
surgical team 
• an optimal biliary drainage to avoid morbidity due to
cholangitis during chemoradiation. 
• Consequently, this strategy should therefore be restricted
to clinical trials. 
New combined regimens
Although the modalities of 5FU-based chemoradiation can
be further explored (neoadjuvant setting, intensified regimen,
continuous infusion for the entire chemoradiation period of 6
weeks), we clearly need more innovative drug regimens in
view of the limited activity of 5FU in metastatic pancreatic
cancer11, 12. This is needed in order to achieve, not only a
better locoregional tumor control, by maximizing additive or
synergistic effects with radiation, but also to treat microscopic
extrapancreatic metastatic disease which is responsible of
most tumour relapses.
Gemcitabine, a deoxycytidine analogue capable of inhibi-
ting DNA replication and repair, has proved more benefitial
than 5FU in advanced pancreatic cancer,with a higher res-
ponse rate (5.4 vs 0%), greater clinical benefit (23.8 vs 4.8%)
and longer survival (5.65 vs 4.41 months)17. Gemcitabine is
also a potent radiosensitizer of human pancreatic cells in vi-
tro (PANC-1) and in vivo models18-20. 
J. L. Van Laethem y cols.
72
TABLE II
Preoperative chemoradiation based on 5FU regimens in patients with pancreatic cancer
Author (year) (reference) No of patients Treatment Hospitalization rate Median survival (months)
Hoffman (1998) 53 50.4 Gy + 5FU + Mitomycin-C 51% 15.7
(13)
Spitz (1997) 41 30-50.4 Gy + 5FU C 32% 19.2
(14)
Pisters (1998) 35 30 Gy + 5FU 9% 25
(15)
Snady (2000) 68 preop 40 Gy split + 5FU + – 23.6
(16) cisplatin + streptozotocin 
(20/68 curatively resected)
There is now increasing clinical evidence that gemcitabine
administration can be combined with radiation in pancreatic
cancer, both in locally advanced disease and in the setting of
(neo)adjuvant treatment; the most important phase I and II
studies reported so far are shown in Table III. Gemcitabine
was mainly administered weekly (300 to 500 mg/m2 infused
over 30 min IV) or twice weekly (40 mg/m2 X2) with conco-
mitant radiation (30 to 50.4 Gy)21-33. Other approaches in-
cluded giving gemcitabine at a fixed dose of 1000 mg/m2
while increasing the intensity of the weekly dose of radia-
tion34. The overall treatment time was kept constant at 3 we-
eks ( 15 fractions of radiation) and the total dose was increa-
sed from 24 Gy to 42 Gy. The authors recommend 36 Gy in
2.4 Gy fractions on the basis of tolerance, patterns of failure
and survival data. 
All these regimens exhibited good feasibility and accepta-
ble, although not negligible toxicity So far, approximately 10
phase I-II studies including a median of 17 patients (range
:8-58) have been reported, with a rate of grade 4 toxicity
(mainly hematological and gastrointestinal) in less than 20-
25% of the patients, compliance with the treatment of about
80% and no major late reactions observed after a follow-up
period of 12 to 17 months26, 28, 31, 32. The results were quite
promising,as complete and partial responses were observed
both in locally advanced disease and in the neoadjuvant set-
ting. Feasability of gemcitabine combined with radiation the-
rapy in the neoadjuvant setting was recently reported in a
large series of 86 patients30. Although manageable, the hos-
pitalization rate related to the toxicity of this regimen was
high (43%) and underlines the fact that this kind of approach
should be unequivocally restricted to appropriate trials. High
toxicity rates could be attributed to the rapid-fractionated ra-
diotherapeuthic scheme (3 Gy/fraction) as well as the risk of
cholangitis in patients with endobiliary stenting. The activity
of such a combination with high pathological response rate is
appearing. However a survival benefit has not yet been de-
monstrated. 
Gemcitabine based chemoradiation was also successfully
administered in the postoperative adjuvant setting in two re-
ports, showing a good tolerance and no major toxicities 30,
31. In addition to our first study, an intensified post operative
combined regimen was recently assessed using weekly gem-
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TABLE III
Gemcitabine + concomitant radiation: main reports of phases I-II in pancreatic cancer
Author (year) (reference) No of patients Gemcitabine mg/m2/week RT Toxicity (gr 3-4) (nb patients) Activity
Locally advanced disease
Mc Ginn (1998) 13 200-400 50.4 Gy GI –
(21)
Kudrimati (1999) 18 50-150 40 Gy GI (10) 5 CR
(22) (24h inf) 4 PR
Reyes-Vidal (2000) 14 200-325 45 Gy respiratory (1) 2 CR
(23) hepatitis (1) 6 PR
neutro (1) 6 SD
Epelbaum (2002) 20 400 50.4 Gy GI (5) 4 PR
(24) Gr 4 neutro (2) 6 SD
Mustacchi (2001) 15 500 45.55 Gy GI (9) 1 CR
(25) 4 PR
4 SD
Blackstock (2001) 38 2x40 50.4 Gy Gr 4 hemato (6) –
(26 ,27)
Preoperatively
Wolff (1998) 9 400 30 Gy Gr 3 neutro (4) 2 PR
(28)
Hoffman (1998) 18 300-500 50.4 Gy Gr 3 hemato (4) 4 PR
(29) cholangitis (9)
Wolff (2002) 86 400 30 Gy Hospitalization 2 CR
(30) rate 43% PR : 59%
Postoperatively
Van Laethem (2003) 17 300 40 Gy split GI (1) –
(31) Gr 3-4 hemato (3) –
Kachnic (2001) 15 (9) 2x40 50.4 Gy Gr 3 hemato (3) –
(32) GI (1)
Demols (2003) 30 300 45 Gy GI : 30%
(33) Hemato : 32% –
CR: complete response, PR: partial response, SD: stable disease; GI: gastrointestinal; neutro: neutropenia; hemato : hematological; Gr: grade
citabine (300 mg/m2) with 45 Gy continuous radiation In
28/30 patients, tolerance and compliance of treatment were
quite good and toxicity acceptable33.
A recent study compared the therapeutic index of gemcita-
bine-based chemoradiation to that of 5FU-based chemoradia-
tion in patients with locally advanced disease35. Although it
was retrospective, it clearly emphasized that, for comparable
patients receiving similar radiation regimen (30 Gy in 10 frac-
tions), severe acute toxicity was significantly higher in the
group of patients treated with gemcitabine compared to 5FU
(23% vs 2%, p< 0.0001) while recurrence rate and survival
were comparable However, a small number of patients with
minimal arterial involvement whose disease met the radiograp-
hic definition of unresectable disease had margin-negative re-
sections after treatment with gemcitabine-based chemoradia-
tion35. Therefore, some selected patients could probably benefit
from a such neoadjuvant approach inside clinical trials. 
Based on the previously reported data,it seems warranted
to use gemcitabine in the adjuvant setting of pancreatic can-
cer, as this agent may help to control both micrometastatic
dissemination and local recurrence when combined with con-
comitant radiation. However, the above mentioned data sug-
gest that the therapeutic ratio for this type of combination
may be narrow It should also be noted that an extremal level
of patients selection has gone into these pilot trials; therefore
such combinations are not yet suitable for general use and
should be further and more widely evaluated in prospective
phase II trials.
Other new agents that will be assessed more deeply in the
near future include paclitaxel which has revealed promising
activity as a radiosensitizer (response rates of 26-29% in lo-
cally advanced disease) and limited toxicity in preliminary
reports36, 37 and other drugs like cisplatin, oxaliplatin or bio-
logical agents targeted to the Epidermal Growth Factor re-
ceptor or Her-neu2 receptor in combination or not with ra-
diation38-42.
Perspectives in the adjuvant setting
Previous trials have led to conflicting or underpowered re-
sults. The results of large but retrospective and non-randomi-
zed single institution experiences, or of randomized, but
small trials like those conducted by the GITSG or the EORTC
suggest that adjuvant chemoradiation may be beneficial, alt-
hough the EORTC trial was probably an underpowered posi-
tive trial rather than a negative one as mentioned above5,10.
On the other hand, investigators involved in the large ES-
PAC-1 trial reported a survival benefit for 5FU-based che-
motherapy only, while they claimed that chemoradiation has
a confounding negative effect on the benefit of chemotherapy
alone9; the criticisms concerning this study have been outli-
ned above and the conclusions drawn from this trial should
likely not change our standard practice.
What are the major directions that we have to follow for
the creation of new trials in the adjuvant setting? Neoadju-
vant strategies seem clearly attractive, mainly to test the tole-
rance and the activity profile of new coumpounds within the
frame of clinical phase II trials. These should also include tar-
geted therapies after identification of,e.g. Epidermal or Vas-
cular-endothelial growth factor receptors Today, it is pro-
bably too early to propose a large randomized trial taking
into account the possible difficulties to manage such patients
preoperatively.
Addressing the postoperative approach, there are still
controversies on the definition of the standard treatment for
resectable pancreatic cancer. In the US, 5FU-based chemo-
radiation has been considered standard of care, since the re-
ports of the GITSG trial and the 5FU-based chemoradiation
experience This strategy has been incorporated into both
arms of the current RTOG phase III trial (Table IV). The ques-
tion raised by this trial is important: can the addition of gem-
citabine- based chemotherapy to chemoradiation increase
the median survival from 18 months to 25 months as compa-
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TABLE IV
Ongoing trials in the adjuvant setting of pancreatic cancer
TRIAL Treatment arms n patients status 
Observation 330 
• ESPAC 3: R GEM x 6 cycles 330 ongoing
(phase III) 5FU/FA bolus x 6 cycles 330
GEM ( RT + 5FUc ( GEM 2 59 closed
• RTOG 9704 US trial: R
(phase III) 5FU ( RT + 5FUc ( 5 FU 259 
observation 40/ 270 open 
• EORTC-FFCD: R April 03
(phase II-III) GEM x 2 cycles ( RT + GEM 40/270
Observation 235
• German trial: R 
(phase III) GEM x 6 cycles 235 ongoing
GEM: gemcitabine, RT: radiation = 50.4 Gy in 28 fractions of 1.8 Gy/fraction
red with a 5FU based chemotherapy; the study is now closed
after enrollment of 518 patients and the results of the first da-
ta analysis are awaited. In Europe, it is consensually admit-
ted that surgery alone remains the standard of care. As gem-
citabine alone is currently the standard treatment of metasta-
tic disease, its impact on survival after curative resection is
questionable and two phase III trials are currently in pro-
gress. Subsequently to the ESPAC-1 trial, the ESPAC group
has now launched the ESPAC-3 trial which aims to randomi-
zing 990 patients in three arms comparing 5FU/folinic acid
(Mayo regimen) for 6 months, vs gemcitabine for 6 months
vs observation; the purpose of this trial is to strengthen the
beneficial role of chemotherapy, since the ESPAC investiga-
tors consider that the potential benefit of chemotherapy ob-
served in the ESPAC-1 trial was not clear, because of the ap-
parent negative effect of chemoradiotherapy A randomized
German phase III trial aiming to recruit 470 patients is cu-
rrently exploring the potential beneficial effects of gemcitabi-
ne administered alone in an adjuvant setting(TableIV).
It is tempting to postulate that a combination of chemothe-
rapy and chemoradiation aimed at controlling both local and
distant relapses would be of potential benefit in the adjuvant
setting The combination of gemcitabine with radiation is a
good candidate to be tested in this setting and will deserve
further evaluation in the next future (Table IV). Initial assess-
ment of a good tolerability profile is crucial based on the
preliminary results observed in selected centers (Table III)21-33. 
The results of these trials will be not available for 3 to 5
years. Meanwhile, current and future research is needed to
assess the efficacy of new gemcitabine-based drug combina-
tions adding signal transduction-inhibitors or immunothera-
peutic agents like this, we will profit for a better understan-
ding of the disease for the sake of our patients. 
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